Kornimate/medical-research-clean huggingface dataset:
aortic valve reconstruction using autologous pericardium: single center experience with the ozaki technique

Conditions: Aortic Valve Disease

Summary: the aim of this study is to analyse the short-term results of the first patients undergoing the ozaki procedure (aortic valve reconstruction using autologous pericardial tissue) at the department of cardiac surgery/ university hospital basel/ switzerland.

the reconstruction of the aortic valve using autologous pericardium, applying the technique ozaki et al., published first in 2011 provides potential benefits due to the missing necessity of oral anticoagulation and its use in patients with small aortic annuli, because of the huge orifice area. there is a need of more data to evaluate the significance of this technique in the treatment of aortic valve stenosis and regurgitation. the department of cardiac surgery/ university hospital basel/ switzerland started to use this technique in september 2015. the aim of this study is to analyse the short-term results of the first patients undergoing the ozaki procedure.

Eligibility criteria:
inclusion criteria: * aortic valve reconstruction using autologous pericardium (ozaki technique) exclusion criteria: * missing informed consent

Keywords: aortic valve reconstruction ozaki technique autologous pericardium
lung perfusion measured with dual-energy ct in patients with chronic thromboembolic pulmonary hypertension: comparative study with right heart catheterization and v/q

Conditions: Multidetector Computed Tomography; Pulmonary Embolism and Thrombosis; Hypertension Pulmonary Secondary

Summary: a comparative, observational, cross-sectional and prolective diagnostic test study, including patients that have had a right heart catheterization and were referred for a ct pulmonary angiography as part of their imaging workup protocol for pulmonary hypertension. dual-energy computed tomography (dect) pulmonary angiography was performed on each patient to obtain perfusion maps and do a quantitative analysis. segments with and without perfusion defects according to significant differences in the quantitative values, were defined as compatible or not with chronic thromboembolism. to assess the accuracy of the method and evaluate its performance, these results were compared with the sole results from the right heart catheterization, known to be the gold standard diagnostic tool.

a comparative, observational, cross-sectional and prolective diagnostic test study is conducted, including consecutive patients from the pulmonary hypertension clinic at our institution, from march 2017 to october 2018. patients that have had a right heart catheterization and were referred for a ct pulmonary angiography as part of their imaging workup protocol. (the minimum sample size calculated is 26 patients). dect pulmonary angiography (256-slice and double-source ct scanner) was performed on each patient. obtaining perfusion maps and doing a quantitative analysis by circular regions of interest (roi) and iodine-related attenuation values (ira) on each lung segment. then, according to the finding in right heart catheterization, a comparison will be made between to groups: segments with and without perfusion defects, in order to find significant differences in the quantitative. to assess the accuracy of the method and evaluate its performance, these results were later compared with the sole results from the right heart catheterization. roc curves were plotted to extract possible decision thresholds of the ira values to classify perfusion as normal or deficient with this technique.

Eligibility criteria:
inclusion criteria: * patients from the pulmonary hypertension clinic at our institution who have had right heart catheterization and were referred for a pulmonary ct angiography as part of their imaging workup protocol. exclusion criteria: * creatinine \> 1.5 mg/dl

Keywords: multidetector computed tomography pulmonary embolism hypertension pulmonary secondary
therapy for erectile dysfunction adaptation of act for compliance with an erectile rehabilitation program

Conditions: Prostate Cancer

Summary: the investigators know that treatment for prostate cancer and erectile dysfunction can impact sexual health and quality of life. they want to learn how the treatment affects one's emotional and social well-being. they have developed a new type of counseling. cancer patients seek counseling for lots of reasons. it often helps them cope because they can express their feelings with a trained professional. they hope that this counseling will teach patients skills that they can use to comply with erectile treatment programs, improve their sexual health and quality of life. these skills may also improve physical and emotional well-being. as part of this study they will ask the patient to provide feedback on the proposed counseling.


Eligibility criteria:
inclusion criteria: part a * men who are 1 to 3 years post radical prostatectomy for early stage prostate cancer * participated in penile injection program * are able to speak, read, write and understand english well enough to complete study assessment and communicate with an english speaking therapist part b * men who are up to 9 months post radical prostatectomy. * had good erectile functioning pre-surgery (i.e., 24 or greater on the iief erectile function domain (efd) score), graded their erections as a 1 or 2 on the standard 5 point urology erectile function scale) or have a score of 7 or greater on the 1-10 pre-surgery erectile function scale on the smrp assessment) * seen at mskcc"s sexual medicine rehabilitation program (smrp) * advised by the clinical staff of the smrp to start penile injections. exclusion criteria: part a * recurrence or progression of disease, * specific injection phobia (self report) * a history of bipolar disorder or psychotic disorder (determined from self-report and/or chart review) * current major depression (determined by self report and/or clinician observation and assessment) that would preclude from giving informed consent or being an active participant in a focus group part b * specific injection phobia (self report) * a history of bipolar disorder or psychotic disorder (determined from self-report and/or chart review) * current major depression (determined by self report and/or clinician observation and assessment) that would preclude from giving informed consent or being an active participant in a therapeutic session.

Keywords: erectile dysfunction focus group quality of life 10-204
noninvasive vagal nerve stimulation

Conditions: Multiple Sclerosis

Summary: growing evidence suggests that vagal nerve stimulation (vns) may be novel and effective in the management of the symptom burden of multiple sclerosis (ms) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. we will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (tavns) and transcutaneous cervical vagus nerve stimulation (tcvns) to a standard intervention of dorsolateral prefrontal cortex (dlpfc) transcranial direct current stimulation (tdcs) as an active control. the primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled rct. we will also measure heart rate variability (hrv), an easily obtained biomarker of vagus nerve stimulation (vns), in correspondence to intervention response.


Eligibility criteria:
inclusion criteria: * female * age 25-65 years (inclusive) * definite diagnosis of ms or related demyelinating disorders (e.g., neuromyelitis optica or nmo) * stable high efficacy dmt ≥ 6 months before enrollment and throughout the trial * pdds score ≤ 6 (established to be able to complete procedures) * symptomscreen score ≥12 * wrat-5 ≥85 * sdmt z-score \> -3.0 * k10 \< 35 * stable disease activity, defined as being more than 1 month after a clinical relapse or confirmed radiologic disease activity, or more than 1 month after steroid treatment * ability to use mobile devices exclusion criteria: * primary neurologic disorder other than ms and related demyelinating disorders like nmo (e.g., stroke, parkinson's disease, spinal cord injury, intracranial mass, traumatic brain injury (tbi), epilepsy, mild cognitive impairment (mci), or dementia), psychiatric disorders or major medical disorders (e.g., history of myocardial infarction, diabetes, thyroid disease, arrhythmia, atrial fibrillation) * diagnosis of postural orthostatic tachycardia syndrome (pots) * history of vagus nerve surgery/vagotomy * history of diagnosed cardiovascular disease, a heart transplant, presence of permanent pacemaker implant or left ventricular assist device * use of certain medications that can affect heart rate variability, such as beta-blockers, calcium channel blockers, and cardiac glycosides * use of sp1 inhibitor medications such as fingolimod, siponimod, ozanimod, and ponesimod * nicotine use in the past 6 months (smoking/vaping) * pregnant or planning pregnancy during the study period or breastfeeding * seizure disorder or recent (\<5 years) seizure history * active ear infections or ear pathology * current presence of implanted vagus nerve stimulator or any other active implanted electronic devices (e.g., pacemaker, defibrillators, cochlear implants, dbs, ivns, etc.) * presence of metal objects in the head/neck * any skin disorder or skin sensitive area near stimulation locations * bmi ≥ 35

Keywords: vns tdcs vagus nerve stimulation neuromodulation multiple sclerosis home-based
a comparison of incisionless ultrasound guided thread carpal tunnel release and mini open carpal in patients with bilateral carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome Bilateral

Summary: to compare the incisionless thread carpal tunnel release with the standard mini-open carpal tunnel release (standard of care) in patients with bilateral carpal tunnel syndrome. patients with bilateral cts will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release. the investigators hypothesize that the incisionless thread carpal tunnel release (tctr) will be no different than the standard mini-open release (mor) with regard to symptom improvement and safety and will be less painful, result in quicker return to work and will be less costly.


Eligibility criteria:
inclusion criteria: * a diagnosis of bilateral cts with symptoms including pain, paresthesia's, and weakness of the hand in the median nerve distribution for minimum of 3 months * willingness to undergo bilateral carpal tunnel surgical treatment with one side having the tctr and the other a mini open carpal tunnel release * age 18-65 years of age * clinical examination findings (compression test, tinels, phalens, etc) consistent with carpal tunnel syndrome. * persistence of symptoms after 6 weeks of conservative treatment such as splinting, activity modification, and/or injection therapy. * electromyographic evidence of mild, moderate, moderately severe, or severe median nerve neuropathy at the wrist * able and willing to complete all follow-up appointments exclusion criteria: * previous cts surgical release on any of their hands * diabetes mellitus * hypothyroidism * significant hand arthritis (rheumatologic or osteoarthritis) * pregnancy * electromyographic evidence of any condition other than cts affecting the hand * workman's compensation
primary versus secondary closure of stoma-reversal skin wound

Conditions: Wound Infection

Summary: to compare infection rate stoma reversal skin wound after primary or secondary closure

there will be two groups. in group a, skin will be stitched with prolene while in group b skin will be left open to follow up till 1 month and wound observed for infection according to cdc guidelines.

Eligibility criteria:
inclusion criteria: * . all patients who undergo ileostomy or colostomy reversal will be included exclusion criteria: * included patients with reversal of stoma through laparatomy, post-operative anastomotic leak and co-morbidities like diabetes, chronic liver disease, chronic kidney disease etc

Keywords: skin closure stoma reversal
effects of rosiglitazone and alpha-lipoic acid on the patients with pathologically proved nash

Conditions: NASH (Non-alcoholic Steato-hepatitis)

Summary: this study is to evaluate the effects of rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved nash (non-alcoholic steato-hepatitis).

duration: 24 week-intervention study group: four arms * control: no intervention * rosiglitazone: rosiglitazone (8 mg/day) * alpha-lipoic acid: alpha-lipoic acid (1800 mg/day) * rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)

Eligibility criteria:
inclusion criteria: * the patients with pathologically proved nash (non-alcoholic steato-hepatitis) exclusion criteria: * alcohol consumption \> 20g/day * viral hepatitis b and c * autoimmune hepatitis * wilson's disease * hemochromatosis * alpha-1 antitrypsin deficiency * breast-feeding or pregnant females * subjects planning to become pregnant * severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems) * those not consenting for the study
prophylactic antibiotic treatment during vaginal repair

Conditions: Uterine Prolapse; Cystocele; Rectocele; Enterocele

Summary: prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or elderly women. the number of operations for vaginal repair is increasing in denmark, but there is no consensus or evidence found about the efficiency of prophylactic antibiotics intraoperatively concerning postoperative infections. the objective of this randomized, controlled trial is to investigate the significance of prophylactic antibiotic treatment in vaginal repair operations.


Eligibility criteria:
inclusion criteria: * women ages 18+ with uterine prolapse grade i - ii and/or cystocele and/or rectocele and/or enterocele grade i - ii and/or defects of the perineal body, in whom there is medical indication for vaginal repair, but no indication for vaginal hysterectomy or transvaginal suspension of the vaginal vault after prior hysterectomy. exclusion criteria: * patients allergic to cefuroxime. * patients in whom a vaginal hysterectomy or a transvaginal suspension of the vaginal vault or other major surgery is planned, where prophylactic antibiotic treatment is standard. * patients suffering from physical or mental disorders that will not allow them to give informed consent. * pregnant and nursing women.

Keywords: prophylactic antibiotic postoperative infections uterine prolapse grade i - ii cystocele rectocele enterocele defects of the perineal body
barbed suspension of the tongue base for treatment of obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea syndrome (osas) is a common clinical condition in which the throat narrows or collapses repeatedly during sleep, causing obstructive sleep apnea events. one of the most common sites for collapse during sleep is hypo-pharyngeal space. it was founded in 50% of osa patients those have moderate and severe apnea. derowe et al invented the tongue base suspension operation in 1998 for sleep disordered breathing.


Eligibility criteria:
inclusion criteria: * bmi of patients less than 35 kg/m2. * patients who have symptoms and signs of osa. * moderate to severe osahs confirmed by formal polysomnography (defined as an ahi ≥15). * friedman tongue position iii or iv. * documented failure/refusal of attempts of conservative treatment measures (not limited to continuous positive airway pressure). * the presence of retrolingual collapse confirmed preoperatively with flexible fiberoptic endoscope during muller maneuver. * patients have macroglossia as defined by posterior airspace (pas) of ≤10mm. exclusion criteria: * failure to attend postoperative follow-up polysomnography within 6 months of surgery. * previous surgery to the base of the tongue or other surgical treatment of osahs. * a history of malignancy or infection of the head and neck region, laryngeal trauma, or other previous oropharyngeal/laryngeal surgery. * patients have retrognanthia sella-nasion-supra mentale (snb) ≥76º. * huge lymphoid tissue of the tongue and/or lingual tonsil.

Keywords: tongue base tongue base suspension barbed suture
increasing uptake of colorectal cancer screening in ontario

Conditions: Colorectal Disorders

Summary: the investigators hope to determine whether the addition of an fobt kit and educational materials to a second mailed invitation compared to a second mailed invitation alone increases use of appropriate screening tests (fobt for average risk or colonoscopy if increased risk) by eligible persons within 6 months of the second mailing in: (1)non-responders to an initial mailed crc screening invitation from their family physician and, (2)those who responded to the initial mailed crc screening invitation and are due for repeat screening (i.e., "recall" patients). in addition, the investigators will also explore the impact of the investigators intervention in likely under-screened groups such as those living in more remote areas of the province and those with low socio-economic status as well as assessing the cost-effectiveness of this strategy.


Eligibility criteria:
inclusion criteria: * recipients of a mailed crc screening invitation through the cco invitation pilot project * no ohip record of completion of fobt since initial mailing (non-responders arm only) * no ohip of 'crc cancer screening exclusion' tracking code since initial mailing (non-responders arm only) * an ohip record of completion of fobt 6 months since initial mailing (recall arm only) * negative result according to lrt or if not in lrt, no record of interval colonoscopy in cirt or ohip (recall arm only) exclusion criteria: * age greater than 74 years at time of mailing * interval diagnosis of colorectal cancer * interval colonoscopy or flexible sigmoidoscopy * interval departure from pilot physician's practice * death * presently institutionalized * physician has declined participation in the study * interval record of repeat fobt (recall arm only)

Keywords: colorectal cancer screening fecal occult blood testing mailed invitation
irinotecan in treating patients with refractory solid tumors and liver dysfunction

Conditions: Unspecified Adult Solid Tumor; Chemotherapy; Liver Dysfunction; Neoplasms, Solid Tumor

Summary: drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.


Eligibility criteria:
other specific inclusion/exclusion criteria may apply. in order to determine eligibility, further examination by the investigator is necessary. inclusion criteria: histological proof of malignant solid tumor that is refractory to standard forms of therapy or for which no known curative therapy exists; measurable or evaluable disease; at least 6 weeks since prior chemotherapy with nitrosoureas; at least 28 days since prior anticancer therapy and recovered; at least 4 weeks since prior radiation therapy and recovered; age 18 years or older; swog 0-2; life expectancy of at least 12 weeks; segmented neutrophils with bands at least 1,500/mm3; hemoglobin at least 9.0 g/dl and platelet count at least 100,000/mm3; prothrombin time and partial thromboplastin time no greater than 2.0 times control; inr no greater than 3.0 times control; concurrent use of coumadin allowed only if dose is stable and prothrombin time and inr is stable; total serum bilirubin at least 1.5 but no greater than 5.0 times upper limit of normal; sgot/sgpt no greater than 5 times upper limit of normal; sgot/sgpt at least 1.5 but no greater than 20.0 times upper limit of normal; creatinine no greater than 2 exclusion criteria: patients expressing tumor markers as their only evidence of disease or who have previously irradiated areas that have not increased in size; prior chemotherapy treatment with irinotecan and mitomycin; prior abdominal and/or pelvic radiation therapy; current history of hepatitis b infection or positive test for hepatitis b surface antigen; hepatic encephalopathy including somnolence, confusion, or asterixis; history of myocardial infarction within 6 months or history of congestive heart failure (chf); clinical evidence of chf; evidence of arrhythmia in patients with history of cardiac arrhythmia; uncontrolled hypertension, unstable angina, active chf, or serious uncontrolled cardiac arrhythmia; interstitial pneumonia or fibroid lung (patients must have large pleural effusions drained and sclerosed or controlled prior to study; patients must have clinically apparent ascites drained prior to irinotecan treatment); cns metastases or carcinomatous meningitis; concurrent use of anticonvulsants; active or uncontrolled

Keywords: pharmacia
association between carotid plaque length and cardiovascular events

Conditions: Coronary Arteriosclerosis

Summary: this multicenter study involved 5 hospitals (changhai hospital; yueyang hospital of shanghai university of traditional chinese medicine; gongli hospital; putuo hospital of shanghai university of traditional chinese medicine; no. 904 hospital of the pla joint logistics support force wuxi). the study enrolled 3637 patients with coronary atherosclerosis who were confirmed by coronary angiography from january 2017 through december 2018.

patients with coronary atherosclerosis who were confirmed by coronary angiography were eligible for the study. carotid ultrasonography was simultaneously performed, and carotid intima-media thickness (imt), maximum thickness and length of all plaques were measured.

Eligibility criteria:
inclusion criteria: * patients≥18 years old, those who underwent carotid ultrasonography and first coronary angiography simultaneously. exclusion criteria: * patients with known coronary artery disease, previous coronary or carotid revascularization, missing carotid ultrasound or coronary angiography results.

Keywords: carotid artery ultrasound carotid plaque coronary artery disease